United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

UNITED THERAPEUTICS Corp

2025-FY EPS reported $27.86 revenue$3,182,700,000

FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.
Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).
Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).
Orenitram sales $496.9M (+14% YoY).
Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.